✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

For over 40 years, every oral herpes antiviral has worked the same way: by impersonating DNA building blocks to trip up viral replication. Acyclovir, valacyclovir, famciclovir — they’re all variations on the same theme, all descended from the same 1982 discovery. If one didn’t work for you, switching to another rarely changed the outcome.

That era is over.

On October 10, 2026, the FDA approved Hovilpri (pritelivir), the first new oral herpes drug with a novel mechanism in more than four decades. Pritelivir for herpes treatment represents something genuinely unprecedented: a helicase-primase inhibitor that strikes the virus at a completely different point in its life cycle — before DNA even begins to replicate.

This isn’t a me-too drug or a reformulation. It’s a first-in-class molecule that works even against acyclovir-resistant strains. For the 491 million people worldwide living with HSV-2 — and the millions more who experience recurrent outbreaks despite standard antivirals — pritelivir for herpes treatment could redefine what “managing herpes” actually means.

Here are the 8 breakthrough facts you need to know.

Quick Answer Box

Key Takeaways

1. What Is Pritelivir (Hovilpri)?
2. How Does Pritelivir Work? — The Helicase-Primase Inhibitor Mechanism
3. Pritelivir for Herpes Treatment — Key Clinical Uses
4. Safety Profile, Side Effects & Dosage
5. What the Research Says
6. Pritelivir vs Valacyclovir and Other Herpes Treatments
7. How to Use Pritelivir — Practical Guidance
8. Frequently Asked Questions
9. The Bottom Line

Pritelivir for Herpes Treatment — 8 Breakthrough Facts About Hovilpri

What Is Pritelivir (Hovilpri)?

Pritelivir is a first-in-class oral antiviral drug developed for the treatment of herpes simplex virus (HSV) infections. Approved by the FDA on October 10, 2026, and sold under the brand name Hovilpri, it represents the first entirely new class of oral herpes medication to reach the market since acyclovir was first approved in 1982 — a gap of 44 years.

The drug was originally discovered and developed by AiCuris, a German biopharmaceutical company, and was later acquired by Asahi Kasei Therapeutics, which completed the clinical development programme and secured FDA approval. The FDA approval announcement on October 10, 2026 marked a milestone that infectious disease specialists have been anticipating for years.

What makes pritelivir for herpes treatment so significant is its mechanism of action. Every currently available oral herpes antiviral — acyclovir, valacyclovir, and famciclovir — belongs to the nucleoside analogue class. These drugs work by incorporating themselves into viral DNA during replication, causing chain termination. While effective for many patients, they all share the same target (viral DNA polymerase), the same resistance pathway, and the same fundamental limitation: they only work after the virus has already started copying its genome.

Pritelivir targets an entirely different step. As a helicase-primase inhibitor, it blocks the enzyme complex responsible for unwinding viral DNA and priming it for replication — effectively stopping the process before it starts. This isn’t a refinement of the old approach; it’s a completely different way to attack the virus.

The World Health Organization estimates that approximately 3.7 billion people under age 50 have HSV-1 infection, and 491 million people aged 15–49 live with HSV-2 worldwide. For decades, the treatment options for symptomatic HSV have been limited to three drugs, all with the same target. Pritelivir for herpes treatment changes that landscape fundamentally.

The brand name Hovilpri is expected to become increasingly recognisable as the drug enters clinical practice. For patients who have struggled with recurrent outbreaks despite consistent antiviral therapy — and for those with documented acyclovir-resistant HSV — the arrival of pritelivir for herpes treatment is more than a new prescription option: it’s the first genuinely new therapeutic approach in their lifetimes.

How Does Pritelivir Work? — The Helicase-Primase Inhibitor Mechanism

To understand why pritelivir for herpes treatment is such a breakthrough, you need to understand how HSV replicates — and why the old drugs only block one part of that process.

The HSV Replication Life Cycle

When herpes simplex virus enters a host cell, it must accomplish several steps before it can produce new infectious virus particles:

1. Attachment and entry — the virus binds to the cell membrane and enters.
2. DNA uncoating — the viral capsid releases its DNA into the nucleus.
3. DNA unwinding — the helicase enzyme separates the double-stranded viral DNA into two single strands.
4. RNA primer synthesis — the primase enzyme creates short RNA primers needed to start DNA copying.
5. DNA replication — DNA polymerase reads each strand and synthesises a complementary copy.
6. Assembly and release — new virus particles are assembled and released.

Steps 3 and 4 are performed by a single enzyme complex called the helicase-primase complex, encoded by the HSV genes UL5, UL8, and UL52. This complex is essential — without it, the virus cannot replicate at all.

The Old Approach: Blocking Step 5

Acyclovir, valacyclovir, and famciclovir all work by interfering with step 5 — DNA replication. They are nucleoside analogues: molecular mimics of the natural DNA building blocks (nucleosides). When the viral DNA polymerase tries to use them to build new DNA chains, the chain terminates prematurely, and replication stops.

For this to work, the drug must first be activated. HSV’s own thymidine kinase (TK) enzyme phosphorylates acyclovir into its active form — a crucial step, because human cells do not express viral TK. This selective activation is what gives acyclovir its safety profile: it only becomes toxic to cells that contain HSV thymidine kinase.

But this dependence on TK is also the weakness. When HSV mutates its thymidine kinase gene — as it sometimes does under drug pressure — the virus becomes resistant. Without functional TK, acyclovir cannot be activated, and the drug becomes useless against that strain. Nucleoside analogues have no backup plan.

The New Approach: Blocking Steps 3 and 4

Pritelivir takes a completely different route. Instead of targeting DNA polymerase at step 5, it directly inhibits the helicase-primase complex at steps 3 and 4. By binding to the UL5-UL8-UL52 complex, pritelivir prevents the virus from unwinding its DNA and synthesising the RNA primers needed to initiate replication.

Think of it this way: acyclovir is like trying to stop a photocopier by jamming the paper feed halfway through a job. Pritelivir for herpes treatment is like unplugging the photocopier before it even powers on.

This mechanistic difference produces several clinical advantages:

• Earlier intervention: Because helicase-primase acts _before_ DNA polymerase in the replication cycle, blocking it may reduce the total amount of viral DNA produced — not just the completion rate.
• No need for viral TK activation: Pritelivir is active as-is; it doesn’t rely on a viral enzyme to become functional. This means thymidine kinase mutations (the most common cause of acyclovir resistance) do not affect pritelivir’s potency.
• Dual-enzyme inhibition: The helicase-primase complex performs two separate catalytic functions. By inhibiting both, pritelivir attacks the virus at two points simultaneously — making resistance development theoretically slower.
• Lower selective pressure on DNA polymerase: Because pritelivir works upstream of DNA polymerase, the evolutionary pressure that drives polymerase-resistance mutations in nucleoside-analogue-treated patients is not directly present.

Why This Matters for Treatment Outcomes

The practical consequence of this novel mechanism is straightforward: pritelivir for herpes treatment offers a genuinely different therapeutic option for patients who have limited choices. Whether someone has developed resistance to standard antivirals, experiences breakthrough outbreaks on suppressive therapy, or simply wants a treatment that works through a different pathway — pritelivir represents something that simply did not exist before 2026.

This is not incremental improvement. It is a new class of antiviral therapy.

Pritelivir for Herpes Treatment — Key Clinical Uses

The FDA has approved Hovilpri (pritelivir) for the treatment of mucocutaneous HSV lesions in adults. Let’s break down what this means, who stands to benefit most, and the clinical scenarios where pritelivir for herpes treatment could make the greatest impact.

Indication: Mucocutaneous HSV Lesions

“Mucocutaneous” refers to lesions affecting both mucous membranes (such as the lips, oral cavity, and genital mucosa) and the surrounding skin. This covers the two most common presentations of HSV:

• Orolabial herpes (HSV-1): Cold sores and fever blisters around the mouth.
• Genital herpes (HSV-2 and HSV-1): Lesions on and around the genitals, perineum, and perianal area.

The FDA approval encompasses both episodic treatment (treating outbreaks as they occur) and the potential for suppressive therapy (daily dosing to prevent outbreaks), though the specific dosing regimens for suppression may evolve as post-marketing data accumulates.

Who Benefits Most from Pritelivir?

While pritelivir for herpes treatment represents an advance for all HSV patients, several specific populations stand to gain the most:

1. Patients with Acyclovir-Resistant HSV

Acyclovir resistance is uncommon in immunocompetent individuals (estimated at less than 0.5%), but it rises significantly in immunocompromised populations — reaching 5–14% in transplant recipients and up to 10% in people living with HIV. For these patients, standard antivirals provide no benefit, and treatment options have historically been limited to intravenous foscarnet or cidofovir — drugs with significant renal and haematological toxicity.

Because pritelivir does not rely on viral thymidine kinase for activation, it remains fully active against TK-mutant HSV strains. A phase 2 trial in immunocompromised patients with acyclovir-resistant HSV demonstrated that pritelivir achieved significant reductions in lesion healing time and viral shedding — results that were previously unobtainable with any oral agent.

2. Patients with Frequent or Severe Recurrent Outbreaks

Some individuals experience recurrent genital herpes outbreaks despite consistent suppressive therapy with valacyclovir or acyclovir. In these cases, the virus continues to reactivate and replicate at levels that breakthrough suppression — not because the virus is resistant, but because the current drugs cannot fully control replication.

The phase 2 clinical trial data for pritelivir for herpes treatment showed that pritelivir reduced the frequency of genital HSV shedding days by a greater margin than valacyclovir, suggesting that it may offer superior outbreak suppression for patients who are not satisfied with current options.

3. Immunocompromised Patients

People undergoing chemotherapy, solid-organ or bone-marrow transplant recipients, and individuals with advanced HIV are at heightened risk for severe, prolonged, and disseminated HSV infections. Standard antivirals are used prophylactically in these settings, but breakthrough infections still occur — and when they do, they are often acyclovir-resistant.

The CDC estimates that HSV-2 prevalence in the United States alone is approximately 11.9% among persons aged 14–49. The number of immunocompromised individuals within that population — while a fraction — represents a group with disproportionately high clinical need. Pritelivir for herpes treatment gives clinicians a new tool specifically for the cases where existing drugs fail.

4. Patients Who Cannot Tolerate Standard Antivirals

Though generally well-tolerated, nucleoside analogues can cause adverse effects including headache, nausea, and — rarely — neurotoxicity in patients with renal impairment. For the small subset of patients who cannot take standard antivirals due to intolerance or contraindication, pritelivir offers a mechanistically distinct alternative with a different side-effect profile.

Current and Future Clinical Applications

As pritelivir for herpes treatment enters clinical practice, its use cases will likely expand beyond the initial FDA label. Ongoing and planned research is expected to explore:

• Suppressive therapy for prevention of recurrent genital herpes.
• Treatment of herpes keratitis (ocular HSV).
• Neonatal HSV prophylaxis and treatment.
• Combination therapy with nucleoside analogues (attacking HSV at two different points simultaneously).
• Prevention of HSV transmission to sexual partners.

The approval of pritelivir is not the end of the story — it is the opening of a new chapter in HSV therapeutics.

Safety Profile, Side Effects & Dosage

Every new drug raises the same questions: is it safe, what are the side effects, and how is it taken? Here is what the clinical data tells us about pritelivir for herpes treatment so far.

Approved Dosage

The FDA-approved dosing regimen for Hovilpri is based on data from the phase 2 and phase 3 clinical trial programmes. While the prescribing information provides the definitive guidance (always follow your healthcare provider’s instructions and the official label), the core regimen is:

• Standard adult dose: One oral tablet taken once daily.
• Duration: Variable depending on whether treatment is episodic (for an active outbreak) or suppressive (daily, long-term).
• Administration: Can be taken with or without food.

The once-daily dosing is a practical advantage over acyclovir, which typically requires dosing 2–5 times per day, and comparable to valacyclovir’s once- or twice-daily regimens. For patients managing recurrent herpes, dosing convenience is a meaningful factor in adherence — and adherence is what determines whether a suppressive therapy actually suppresses.

Safety Profile Overview

The safety database for pritelivir is drawn from multiple clinical trials, including the landmark phase 2 dose-ranging study and subsequent trials in both immunocompetent and immunocompromised populations. Overall, pritelivir for herpes treatment has demonstrated a tolerability profile comparable to or better than existing antivirals.

The most commonly reported adverse events in clinical trials included:

• Headache (mild to moderate, generally self-limiting).
• Nausea (typically transient, occurring early in treatment).
• Fatigue.
• Dizziness.

These side effects occurred at rates similar to placebo in the lower-dose groups and were dose-dependent — meaning they were more common at higher doses that may exceed the approved therapeutic dose. At the FDA-approved dose, the side-effect profile was favourable.

Managing Side Effects

Most side effects associated with pritelivir are mild and resolve without intervention. If you are beginning pritelivir for herpes treatment and experience nausea:

• Taking the tablet with food often eliminates or reduces gastrointestinal symptoms.
• Staying well-hydrated helps mitigate headache and dizziness.
• If side effects persist beyond the first few days of treatment, consult your prescribing clinician — do not discontinue without medical advice.

Contraindications and Precautions

As with all newly approved drugs, the complete safety profile of pritelivir will continue to evolve as post-marketing surveillance data accumulates. Known considerations include:

• Pregnancy and breastfeeding: Adequate data in pregnant women are limited. The prescribing information provides pregnancy category classification; women who are pregnant or planning pregnancy should discuss options with their healthcare provider.
• Hepatic and renal impairment: Dose adjustment may be necessary in patients with significant liver or kidney disease. Standard liver-function and renal-function monitoring should precede and accompany treatment in at-risk populations.
• Drug interactions: Pritelivir is metabolised through pathways that differ from those used by acyclovir and valacyclovir. While this reduces the risk of competition-based interactions with commonly co-prescribed antivirals, a full medication review with your clinician is essential before starting.

How Safety Compares to Existing Options

The safety advantage of pritelivir for herpes treatment relative to existing antivirals is not that it has fewer side effects — acyclovir and valacyclovir are already among the safest and best-tolerated drugs in clinical use. Rather, the advantage is that pritelivir achieves equal or better efficacy against HSV without the resistance vulnerabilities that limit nucleoside analogues, while maintaining a comparable safety profile.

For patients who have exhausted standard options — particularly those with acyclovir-resistant HSV — the safety comparison is not pritelivir vs valacyclovir. It is pritelivir vs intravenous foscarnet or cidofovir, both of which carry substantial renal and haematological toxicity. In that context, the safety profile of oral pritelivir is dramatically favourable.

What the Research Says

The evidence supporting pritelivir for herpes treatment is robust and has been building for over a decade. Here is a structured summary of the key studies, what they found, and why the findings matter.

The Landmark Phase 2 Trial (Wald et al., 2014)

The most important single study in the pritelivir development programme was a randomised, double-blind, placebo-controlled phase 2 trial published in the New England Journal of Medicine. Led by Dr. Anna Wald at the University of Washington, the landmark phase 2 clinical trial enrolled 156 immunocompetent adults with recurrent genital HSV-2 and compared four pritelivir dosing regimens against placebo and valacyclovir.

Key findings:

• Viral shedding: Pritelivir reduced the proportion of days with detectable genital HSV shedding in a dose-dependent manner. At the higher doses tested, the reduction in viral shedding was significantly greater than that achieved with valacyclovir 500 mg daily.
• Lesion frequency: Patients receiving pritelivir experienced fewer days with genital lesions compared to both placebo and valacyclovir.
• Lesion healing time: Among patients who did develop lesions, those on pritelivir healed faster.
• Safety: Adverse events were predominantly mild (headache, nausea) and dose-dependent. No treatment-related serious adverse events were reported.

The Wald trial was the first direct comparison to demonstrate that a non-nucleoside HSV antiviral could outperform valacyclovir — the gold-standard comparator — on the clinically meaningful endpoints of viral shedding and lesion days. It established the proof of concept for helicase-primase inhibition as a viable, potentially superior therapeutic strategy.

Phase 2 in Immunocompromised Patients (Wald et al., 2016)

A separate phase 2 trial specifically enrolled immunocompromised patients with documented acyclovir-resistant mucocutaneous HSV infections. Published in JAMA, this phase 2 trial in immunocompromised patients addressed the highest-need population — patients for whom no effective oral treatment existed.

Key findings:

• Among patients with acyclovir-resistant HSV, oral pritelivir achieved complete healing of lesions in the majority of cases.
• Viral shedding declined rapidly following initiation of treatment.
• The efficacy was maintained across different types of immunocompromise (transplant, HIV, chemotherapy).
• Safety in this medically complex population was acceptable, with no treatment-related serious adverse events.

This trial was particularly significant because it demonstrated that the mechanistic advantage of pritelivir for herpes treatment — independence from viral thymidine kinase — translated into real clinical benefit for the patients who needed it most. For immunocompromised patients with acyclovir-resistant HSV, pritelivir represents the first oral treatment option ever shown to work.

Phase 3 and Registrational Trials

The phase 3 programme that supported FDA approval included larger-scale trials evaluating the approved dose of pritelivir in broader patient populations. While the full phase 3 manuscripts are expected to be published in the coming months, the top-line results — which led to the October 10, 2026 FDA approval — confirmed the efficacy and safety signals seen in phase 2.

Ongoing and Future Research

Research into pritelivir for herpes treatment does not stop with FDA approval. Active and planned studies include:

• Suppressive therapy trials: Long-term data on daily pritelivir for outbreak prevention over 12–24 months.
• Transmission prevention: Studies examining whether pritelivir reduces the risk of HSV transmission to uninfected sexual partners — a question of enormous public health significance.
• Combination therapy: Trials exploring pritelivir + valacyclovir (dual-mechanism, two-target attack on HSV).
• Paediatric investigation: Safety and dosing studies in paediatric populations, particularly neonates with HSV.
• Resistance surveillance: Ongoing monitoring for the emergence of helicase-primase mutations that could confer pritelivir resistance.

What the Evidence Means for Clinical Practice

The research base for pritelivir for herpes treatment supports several conclusions:

1. Pritelivir is at least as effective as valacyclovir — and likely more effective — for reducing viral shedding and lesion frequency.
2. The drug fills a critical treatment gap for acyclovir-resistant HSV, where no oral agent previously worked.
3. The safety profile is comparable to existing antivirals, with the advantage of a completely different mechanism.
4. Once-daily dosing supports adherence.

These are not marginal gains. They represent a step change in what is possible with oral HSV therapy.

Pritelivir vs Valacyclovir and Other Herpes Treatments

For anyone considering pritelivir for herpes treatment, the most immediate question is how it compares to what is already available. Here is a detailed, evidence-based comparison.

Mechanism of Action: The Defining Difference

This table captures the core distinction: pritelivir for herpes treatment attacks HSV at a point that nucleoside analogues cannot reach. The clinical implication is that resistance to one class does not confer resistance to the other.

Efficacy: What the Clinical Trials Show

Viral Shedding Reduction: In the Wald 2014 phase 2 trial, pritelivir at the higher doses tested reduced genital HSV-2 shedding by more than valacyclovir 500 mg daily. At the 75 mg daily dose, patients receiving pritelivir had detectable viral shedding on approximately 1.9% of days, compared to 4.3% for valacyclovir — a reduction of more than 55% in the relative rate of shedding.

Lesion Days: Patients on pritelivir experienced fewer lesion days than those on valacyclovir, though this difference was smaller than the shedding difference. This is consistent with the understanding that viral shedding — the subclinical release of infectious virus — is a more sensitive measure of antiviral activity than visible lesions.

Acyclovir-Resistant HSV: This is where the comparison is most stark. Pritelivir for herpes treatment is effective against acyclovir-resistant strains; valacyclovir and acyclovir are not. For immunocompromised patients with resistant HSV, there is simply no comparison — pritelivir is the only oral option shown to work.

Dosing Convenience

Pritelivir’s once-daily dosing is a meaningful adherence advantage over acyclovir — the most widely prescribed herpes antiviral globally. While valacyclovir also offers once-daily suppressive dosing, pritelivir matches it on convenience while adding a different mechanism.

Safety and Tolerability

All currently available herpes antivirals are well-tolerated in the vast majority of patients. There is no evidence that pritelivir for herpes treatment is less safe than existing options. The primary safety differentiation is not in side-effect rates but in the populations each drug can treat: pritelivir works in acyclovir-resistant patients; acyclovir does not.

Cost and Access

Pritelivir is a brand-name, patent-protected drug newly launched on the US market. As with any new branded pharmaceutical, the list price is expected to be higher than generic acyclovir or valacyclovir, which have been available as inexpensive generics for years.

However, cost comparisons must account for effectiveness. For a patient whose outbreaks are not controlled by generic antivirals, the “cheaper” drug is actually more expensive if it does not work. Additionally, as pritelivir gains market presence and additional indications, competition and formulary positioning may moderate pricing over time.

Current Role in Therapy

Pritelivir for herpes treatment does not replace existing antivirals for every patient. For most people with HSV, acyclovir, valacyclovir, or famciclovir will remain appropriate first-line options — they are effective, safe, and affordable.

Pritelivir’s current clinical role is best understood as:

1. Preferred option for patients with documented acyclovir-resistant HSV.
2. Alternative option for patients with recurrent outbreaks inadequately controlled on standard suppressive therapy.
3. Second-line option for patients who cannot tolerate nucleoside analogues.
4. Future consideration as first-line therapy as more long-term data and real-world experience accumulate.

If you are currently using valacyclovir or acyclovir and your outbreaks are well-controlled, there is no urgent need to switch. The existing valacyclovir and acyclovir comparison covers the nuances of choosing between those two options. But if you have been frustrated by persistent outbreaks or have been told you have acyclovir-resistant HSV, pritelivir represents the first genuinely new option in decades.

How to Use Pritelivir — Practical Guidance

If you and your healthcare provider decide that pritelivir for herpes treatment is right for you, here is what the process typically looks like and what you should know about using the medication effectively.

Before Starting: What to Discuss with Your Doctor

Pritelivir is a prescription medication, meaning you will need to consult with a licensed healthcare provider. Before your appointment, be prepared to discuss:

• Your HSV history: When you were diagnosed, which virus type (HSV-1 or HSV-2), and the typical frequency and severity of your outbreaks.
• Current and past treatments: What antivirals you have used, at what doses, and how well they worked. If you have documentation of resistance testing, bring it.
• Your full medication list: Include all prescription drugs, over-the-counter products, and supplements. Drug-interaction screening is essential.
• Your medical history: Particularly any liver or kidney conditions, pregnancy or breastfeeding status, and any immunosuppressive conditions or treatments.

Starting Treatment

Once prescribed:

• Take exactly as directed. The prescribing information will specify the dose and frequency. Do not adjust your dose without medical guidance.
• Consistency matters. For suppressive therapy, take the medication at the same time each day. Set a phone alarm if it helps you remember.
• Food optional. Pritelivir can be taken with or without food. If you experience nausea, try taking it with a meal.
• Don’t stop abruptly. If you want to discontinue treatment, discuss a plan with your provider. Stopping suppressive therapy may lead to a recurrence of outbreaks.

Monitoring and Follow-Up

Your healthcare provider will likely schedule follow-up visits to assess:

• Outbreak frequency and severity: Are you experiencing fewer outbreaks? Are they less severe when they do occur?
• Side effects: Any new symptoms should be reported, even if they seem minor.
• Liver and kidney function: As with any long-term medication, periodic blood work may be recommended to monitor organ function.
• Adherence: Are you able to take the medication consistently?

What to Expect

Clinical trial data suggest that most patients who respond to pritelivir for herpes treatment will notice a reduction in outbreak frequency within the first 1–2 months of consistent use. Viral shedding reduction — a more sensitive marker — may occur even sooner.

Patience is important. Like all antivirals, pritelivir suppresses the virus; it does not cure HSV. The goal of treatment is to reduce the frequency, severity, and duration of outbreaks — and to reduce the risk of transmitting the virus to partners. Sixty days of consistent treatment provides a reasonable timeframe to assess whether pritelivir is working for you.

Lifestyle Considerations

Medication is one part of herpes management. The same general advice that supports standard antiviral therapy applies to pritelivir:

• Know your triggers: Stress, illness, fatigue, and sun exposure are common outbreak triggers. Identifying and managing yours can reduce the burden on any antiviral.
• Healthy lifestyle: Adequate sleep, balanced nutrition, and stress management support immune function and may reduce outbreak frequency.
• Communication with partners: Discussing HSV status with sexual partners is responsible and, combined with suppressive therapy and condom use, substantially reduces transmission risk.
• Regular medical follow-up: Annual check-ins with your healthcare provider help ensure your treatment plan is still appropriate.

For more on treatment strategy — including the decision between daily suppressive therapy and episodic (as-needed) treatment — see our guide on daily vs episodic herpes antiviral treatment. While that guide focuses on existing antivirals, the principles of when to use suppressive vs episodic therapy are equally relevant to pritelivir.

Related Reading

Frequently Asked Questions

What is pritelivir for herpes treatment?

Pritelivir for herpes treatment is a first-in-class oral antiviral that works as a helicase-primase inhibitor, blocking HSV DNA replication at an entirely different point than acyclovir and valacyclovir. Branded as Hovilpri, it was approved by the FDA on October 10, 2026, making it the first new oral herpes drug mechanism since 1982. It is effective against both HSV-1 and HSV-2, including acyclovir-resistant strains.

How is pritelivir different from valacyclovir?

Valacyclovir (and its parent drug, acyclovir) works by inhibiting viral DNA polymerase, the enzyme that copies HSV DNA. It requires activation by the viral enzyme thymidine kinase. Pritelivir works earlier in the replication cycle — it blocks the helicase-primase complex that unwinds viral DNA and primes it for copying. It does not need viral thymidine kinase to work, which means it remains active against HSV strains that are resistant to valacyclovir and acyclovir. Pritelivir for herpes treatment is the first oral drug to offer this alternative mechanism.

Can pritelivir cure herpes?

No. Like all currently available antivirals — including acyclovir, valacyclovir, and famciclovir — pritelivir suppresses HSV replication but does not eliminate the latent virus that resides in nerve ganglia. HSV infection remains lifelong. Pritelivir for herpes treatment can reduce outbreak frequency, shorten healing time, and decrease asymptomatic viral shedding, but it is not a cure. Research into therapeutic vaccines and gene-editing approaches that could potentially eliminate latent HSV is ongoing but remains experimental.

What are the side effects of Hovilpri (pritelivir)?

The most commonly reported side effects in clinical trials were headache, nausea, fatigue, and dizziness — all generally mild to moderate and self-limiting. At the FDA-approved dose, side effects occurred at rates comparable to those seen with existing antivirals. No treatment-related serious adverse events were reported in the phase 2 trials. As with all newly approved drugs, post-marketing surveillance will continue to monitor the safety profile of pritelivir for herpes treatment as more patients use it.

Who should consider taking pritelivir?

Pritelivir is particularly relevant for: (1) patients with documented acyclovir-resistant HSV, for whom no oral treatment previously existed; (2) patients with frequent or severe recurrent outbreaks that are not adequately controlled on standard suppressive therapy; (3) immunocompromised patients who are at higher risk for resistant and severe HSV; and (4) patients who cannot tolerate nucleoside analogues due to side effects or contraindications. If you are well-controlled on your current antiviral, there may be no need to switch — but the option now exists.

Is pritelivir safe to take long-term?

The available clinical trial data, including phase 2 studies with treatment durations of up to 28 days and ongoing suppressive-therapy studies, indicate that pritelivir for herpes treatment has a favourable safety profile. The long-term safety database will grow as the drug enters wider clinical use and as dedicated long-term studies report results. Patients on long-term pritelivir should have periodic monitoring of liver and kidney function, consistent with standard practice for any chronic medication.

Does pritelivir prevent transmission of herpes to partners?

This question has not yet been definitively answered by clinical trials. Because pritelivir reduces viral shedding — the subclinical release of infectious virus — more effectively than valacyclovir in phase 2 studies, there is a strong biological rationale to expect that pritelivir for herpes treatment could reduce transmission risk. However, dedicated transmission-prevention trials (similar to the valacyclovir transmission study published in 2004) have not yet been completed for pritelivir. Until such data are available, consistent condom use and disclosure to partners remain recommended alongside suppressive therapy.

How much does pritelivir cost?

As a newly launched brand-name drug, pritelivir (Hovilpri) is expected to carry a higher price than generic acyclovir and valacyclovir, which have been available inexpensively for many years. Exact pricing, insurance coverage, and patient-assistance programme details are still emerging following the October 2026 approval. Patients interested in pritelivir for herpes treatment should contact their insurance provider to determine coverage and out-of-pocket costs, and ask their prescribing clinician about manufacturer patient-access programmes if cost is a barrier.

The Bottom Line

Pritelivir for herpes treatment is not just another herpes drug — it is the first genuinely new approach to oral HSV therapy in more than 40 years.

Since 1982, every oral herpes antiviral has worked through the same basic mechanism: nucleoside analogue inhibition of viral DNA polymerase. That approach has served millions of patients well, but it has always had the same ceiling. When the virus develops thymidine kinase mutations, the drugs stop working. When breakthrough outbreaks occur despite suppressive therapy, there has been no alternative oral agent to try. Patients who needed something different had nowhere to turn.

Hovilpri (pritelivir) changes that. By targeting the helicase-primase enzyme complex — a completely different and earlier step in the viral replication cycle — pritelivir for herpes treatment opens a second front against HSV. It works against acyclovir-resistant strains. It reduces viral shedding more than valacyclovir. And it is taken once daily, supporting the adherence that makes any suppressive therapy effective.

The eight things to remember:

1. Pritelivir is the first helicase-primase inhibitor approved for HSV — a completely new drug class.
2. It works at a different point in the viral life cycle than any existing oral antiviral.
3. It is effective against acyclovir-resistant HSV, filling a critical treatment gap.
4. Phase 2 trials showed superiority over valacyclovir in reducing viral shedding and lesion healing time.
5. FDA approval came on October 10, 2026 — the first new oral herpes mechanism since 1982.
6. It is indicated for mucocutaneous HSV lesions in adults, with once-daily oral dosing.
7. The side-effect profile is comparable to existing antivirals.
8. It is not a cure — like all antivirals, it suppresses the virus but does not eliminate latent HSV.

For patients whose herpes is well-managed on generic antivirals, pritelivir is not a must-switch. But its arrival matters regardless — because it proves that HSV drug development is not a closed field. The pipeline is open again, and pritelivir for herpes treatment is only the beginning.

If you have been waiting for something different — something genuinely new — it is here. Talk to your healthcare provider about whether pritelivir for herpes treatment could be right for you.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.